Literature DB >> 17690713

Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease.

Stephen D Miller1, Danielle M Turley, Joseph R Podojil.   

Abstract

The development of safe and effective antigen-specific therapies is needed to treat patients with autoimmune diseases. These therapies must allow for the specific tolerization of self-reactive immune cells without altering host immunity to infectious insults. Experimental models and clinical trials for the treatment of autoimmune disease have identified putative mechanisms by which antigen-specific therapies induce tolerance. Although advances have been made in the development of efficient antigen-specific therapies, translating these therapies from bench to bedside has remained difficult. Here, we discuss the recent advances in our understanding of antigen-specific therapies for the treatment of autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17690713     DOI: 10.1038/nri2153

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  137 in total

1.  Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells.

Authors:  Joel N H Stern; Derin B Keskin; Zenichiro Kato; Hanspeter Waldner; Sonja Schallenberg; Ana Anderson; Harald von Boehmer; Karsten Kretschmer; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-20       Impact factor: 11.205

Review 2.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

3.  Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.

Authors:  Suchitra Prasad; Adam P Kohm; Jeffrey S McMahon; Xunrong Luo; Stephen D Miller
Journal:  J Autoimmun       Date:  2012-05-28       Impact factor: 7.094

Review 4.  Advancing islet transplantation: from engraftment to the immune response.

Authors:  R F Gibly; J G Graham; X Luo; W L Lowe; B J Hering; L D Shea
Journal:  Diabetologia       Date:  2011-08-10       Impact factor: 10.122

5.  Injectable, Pore-Forming Hydrogels for In Vivo Enrichment of Immature Dendritic Cells.

Authors:  Catia S Verbeke; David J Mooney
Journal:  Adv Healthc Mater       Date:  2015-10-16       Impact factor: 9.933

Review 6.  The role of lymphocytes in the development and treatment of alopecia areata.

Authors:  Hongwei Guo; Yabin Cheng; Jerry Shapiro; Kevin McElwee
Journal:  Expert Rev Clin Immunol       Date:  2015-09-07       Impact factor: 4.473

7.  Immune Response against Autoantigen PLA2R Is not Gambling: Implications for Pathophysiology, Prognosis, and Therapy.

Authors:  Hanna Debiec; Pierre Ronco
Journal:  J Am Soc Nephrol       Date:  2015-12-11       Impact factor: 10.121

8.  Regulatory T cells and Atherosclerosis.

Authors:  Jahaira Lopez Pastrana; Xiaojin Sha; Anthony Virtue; Jietang Mai; Ramon Cueto; In Ae Lee; Hong Wang; Xiao-Feng Yang
Journal:  J Clin Exp Cardiolog       Date:  2012-10-08

Review 9.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

10.  A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC.

Authors:  J Lori Blanchfield; Mark D Mannie
Journal:  J Leukoc Biol       Date:  2010-03       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.